Arvinas, Inc. (NASDAQ:ARVN) Stock Holdings Increased by Nomura Asset Management Co. Ltd.

Nomura Asset Management Co. Ltd. grew its holdings in shares of Arvinas, Inc. (NASDAQ:ARVN) by 36.3% in the third quarter, HoldingsChannel reports. The fund owned 90,870 shares of the company’s stock after buying an additional 24,223 shares during the period. Nomura Asset Management Co. Ltd.’s holdings in Arvinas were worth $2,238,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of the business. Braidwell LP grew its position in Arvinas by 148.3% in the 3rd quarter. Braidwell LP now owns 1,284,472 shares of the company’s stock valued at $31,637,000 after buying an additional 767,242 shares in the last quarter. Baker BROS. Advisors LP acquired a new stake in shares of Arvinas in the 3rd quarter worth approximately $9,989,000. FMR LLC increased its stake in shares of Arvinas by 7.6% during the third quarter. FMR LLC now owns 2,883,604 shares of the company’s stock valued at $71,023,000 after acquiring an additional 204,317 shares during the period. Wasatch Advisors LP increased its stake in shares of Arvinas by 58.3% during the third quarter. Wasatch Advisors LP now owns 435,943 shares of the company’s stock valued at $10,737,000 after acquiring an additional 160,510 shares during the period. Finally, Candriam S.C.A. lifted its position in Arvinas by 32.0% in the second quarter. Candriam S.C.A. now owns 610,458 shares of the company’s stock worth $16,250,000 after purchasing an additional 147,904 shares during the period. 95.19% of the stock is owned by institutional investors and hedge funds.

Arvinas Price Performance

NASDAQ:ARVN opened at $19.50 on Friday. The stock has a market cap of $1.34 billion, a PE ratio of -4.18 and a beta of 1.82. Arvinas, Inc. has a fifty-two week low of $18.51 and a fifty-two week high of $53.08. The stock’s 50-day moving average is $25.52 and its two-hundred day moving average is $26.01.

Arvinas (NASDAQ:ARVN) last announced its quarterly earnings data on Wednesday, October 30th. The company reported ($0.68) EPS for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.20. The company had revenue of $102.40 million for the quarter, compared to analysts’ expectations of $60.56 million. During the same period in the previous year, the firm posted ($1.18) earnings per share. The business’s revenue for the quarter was up 196.0% on a year-over-year basis. On average, equities research analysts anticipate that Arvinas, Inc. will post -3.22 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. BTIG Research started coverage on Arvinas in a research note on Tuesday, December 10th. They issued a “buy” rating and a $69.00 price objective on the stock. Stephens initiated coverage on shares of Arvinas in a research note on Monday, November 18th. They issued an “overweight” rating and a $55.00 price objective on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Arvinas in a research report on Monday, September 9th. BMO Capital Markets dropped their price target on Arvinas from $90.00 to $88.00 and set an “outperform” rating on the stock in a report on Wednesday, November 20th. Finally, Guggenheim reissued a “buy” rating on shares of Arvinas in a research note on Thursday. One research analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $63.50.

Arvinas Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.